Gamma Knife thalamotomy improves tremor drawings in 84% of evaluable patients

In 57 evaluable patients, Gamma Knife thalamotomy improved tremor assessments in 84%, while 26.5% of those with clinical follow-up reported adverse effects.

KEY POINTS

  • This retrospective single-institution study from Tacoma/Valley Radiation Oncology Centers, Washington, evaluated Gamma Knife radiosurgery for medication-refractory essential and Parkinsonian tremor between 2005 and 2023. Among 105 initially treated patients, 96 had sufficient baseline data, including 84 with essential tremor (87.5%) and 12 with Parkinsonian tremor (12.5%). Median age was 76 years. The primary efficacy analysis was restricted to 57 patients with paired pretreatment and post-treatment Archimedes spiral drawings, while safety analyses included 68 patients with documented clinical follow-up.
  • Treatment targeted the contralateral ventral intermediate (Vim) nucleus of the thalamus using a single 4-mm Gamma Knife isocenter. Among 84 patients with documented completed treatments, 80 (95.2%) received 130 Gy, while two received 125 Gy and two received 120 Gy. Dose selection was individualized according to anatomy and tremor severity, but the very small lower-dose groups prevented meaningful analysis of dose-response or dose-toxicity relationships.
  • Improvement in tremor was documented in 48/57 evaluable patients (84.2%), based on reduced wave frequency or termination of tremor-related abnormalities in Archimedes spiral drawings, supported by clinician-documented functional improvement. Among patients with essential tremor, 40/49 (81.6%) improved, while 8/8 evaluable patients with Parkinsonian tremor (100%) demonstrated improvement. The difference between diagnostic groups was not statistically significant (Fisher exact p=0.33), and the Parkinsonian subgroup was too small to establish differential efficacy.
  • Treatment response did not show a significant association with patient age or tremor duration. Age was not a significant predictor of improvement (OR 1.08, 95% CI 0.98–1.21; p=0.15). Among 50 patients with available tremor-duration data and paired assessments, improvement occurred in 13/14 patients (92.9%) with symptoms lasting less than five years, 18/22 (81.8%) with five to 15 years, 6/9 (66.7%) with 15–30 years, and 5/5 (100%) with more than 30 years of tremor. These differences were not significant (p=0.34) and should not be interpreted as evidence of equivalent effectiveness across disease durations.
  • Some patients experienced persistent or recurrent symptoms despite initial treatment. Among the 57 patients with paired spiral assessments, three (5.3%) experienced tremor recurrence after an initial improvement, occurring within 1–6 months of treatment. Of the nine patients without documented improvement, three (33.3%) showed worsening tremor on subsequent spiral assessment. Because longitudinal assessments were inconsistent, these figures do not provide reliable actuarial estimates of long-term disease control or sustained functional benefit.
  • Adverse effects were documented in 18/68 patients (26.5%) with clinical follow-up, with a median onset of nine months after radiosurgery. The most frequently reported complications were extremity numbness or weakness in 12/68 (17.6%) and balance or gait impairment in 9/68 (13.2%). Other reported events included fatigue, headache, aphasia, urinary incontinence, and memory difficulties. Approximately half of the documented adverse effects resolved during follow-up, while persistent neurological symptoms were managed with corticosteroids, physical therapy, or hyperbaric oxygen.
  • Incomplete and nonstandardized outcome assessment substantially limits interpretation. Only 57 of 96 baseline-evaluable patients contributed to the primary efficacy analysis, and the median documented clinical follow-up among the safety population was only 9.71 months, close to the median onset of adverse effects. Tremor improvement was assessed through unblinded clinician interpretation rather than a standardized validated tremor scale, and no comparison was performed against deep brain stimulation or MR-guided focused ultrasound. Consequently, the observed response and toxicity proportions may not represent outcomes in the entire treated population.

CLINICAL TAKEAWAY

Gamma Knife thalamotomy was associated with improvement in tremor-related functional assessments among most evaluable patients with medication-refractory essential or Parkinsonian tremor, supporting its consideration when more invasive interventions are unsuitable. However, incomplete follow-up and nonstandardized outcome measurement, combined with potentially delayed neurological toxicity, require cautious interpretation and prospective comparative validation.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction